ArticleFrontiers in psychology2020
Changes of Serum Melatonin, Interleukin-6, Homocysteine, and Complement C3 and C4 Levels in Patients With Depression.
Article in Frontiers in psychology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Altered Cytokine Levels in the First Episode of Major Depression and in Antidepressant-Naïve Patients: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Mood Status Response to Physical Activity and Its Influence on Performance: Are Chronotype and Exercise Timing Affect?International journal of environmental research and public health · 2023Pooled it
- Electroacupuncture enhances the effects of escitalopram oxalate on glucocorticoid-inducible genes, inflammation and neurotrophin in depressed patients.Journal of traditional and complementary medicine · 2026Article
- Clinical Factors and Serum Biomarkers Associated With Major Depressive Disorder in Adolescents With and Without Nonsuicidal Self-Injury: A Comparative Cross-Sectional Study.Alpha psychiatry · 2026Article
- Detailed Review of Melatonin and its Role in Managing the Symptoms of Depression.Current molecular medicine · 2026Review
- Comparative analysis of morning and evening training on performance and well-being in elite soccer players.Physiological reports · 2025Article
- Targeting the complement-mTOR-autophagy axis: the role of apolipoprotein E in depression.BMC biology · 2025Article
- Risk of Cardiovascular Disease Hospitalization After Common Psychiatric Disorders: Analyses of Disease Susceptibility and Progression Trajectory in the UK Biobank.Phenomics (Cham, Switzerland) · 2024Article
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3.Microbiome · 2024Article
- Inflammatory Determinants and Associated Morbidity in Hemodialysis Patients.Journal of personalized medicine · 2023Article
- Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response.Brain, behavior, & immunity - health · 2023Article
- Plasma complement C3 and C3a are increased in major depressive disorder independent of childhood trauma.BMC psychiatry · 2022Article
- Article
- Changes in Levels of Homocysteine and C-Reactive Protein in Patients with Alzheimer's Disease and Their Correlation with Cognitive and UPDRS Functions.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Melatonin as a Reducer of Neuro- and Vasculotoxic Oxidative Stress Induced by Homocysteine.Antioxidants (Basel, Switzerland) · 2021Review
- Plasma homocysteine concentrations and depression: A twin study.Journal of affective disorders reports · 2021Article
- Molecular Regulation of the Melatonin Biosynthesis Pathway in Unipolar and Bipolar Depression.Frontiers in pharmacology · 2021Article
- Exploring Molecular Mechanisms Involved in the Development of the Depression-Like Phenotype in Interleukin-18-Deficient Mice.BioMed research international · 2021Article
- Melatonin and Depression: A Translational Perspective From Animal Models to Clinical Studies.Frontiers in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCytokine activation and low complement levels are common in depression patients. This study is aimed at investigating the clinical significance of changes in serum concentrations of melatonin (MT), interleukin-6 (IL-6), homocysteine (hcy), and complement C3 and C4 in depression patients and relationships of them with depression activity.
methodsA total of 95 depression patients, including first-episode group (
resultsThe serum MT, IL-6, and hcy levels in the first-episode group (113.08 ± 5.06 pg/ml, 2.06 ± 0.12 ng/L, and 13.87 ± 0.45 μmol/L), and recurrent group (117.63 ± 4.63 pg/ml, 2.20 ± 0.12 ng/L, and 13.61 ± 0.46 μmol/L) were significantly higher than those in the control group (89.50 ± 5.10 pg/ml, 1.57 ± 0.06 ng/L, and 11.34 ± 0.40 μmol/L). The serum levels of C3 in the first-episode group (0.95 ± 0.02 ng/L) were significantly lower than those in the recurrent group (1.05 ± 0.03 ng/L) and control group (1.12 ± 0.03 ng/L). There was no significant difference in serum C4 level between each group.
conclusionThese results suggest that higher serum MT, IL-6, and hcy levels were correlated with pathogenesis of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.